A Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Sponsors Sanofi
- 16 Dec 2016 Results published in the Circulation
- 03 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Jul 2015.